Adult Pneumococcal Conjugate Vaccine Approvals Should Not Be Based On Immunologic Data, Advisory Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Vaccine committee upholds FDA opinion that clinical efficacy endpoint studies should be basis of licensure for pneumococcal conjugate vaccine in adults.